Benzyl alcohol improves Ang II-induced vascular and renal injury

Zhenyu Gu1, Qi Hua1

  • 1Department of Cardiology, Affiliated Children's Hospital of Jiangnan University (Wuxi Children's Hospital), Wuxi, Jiangsu, China.

Insights

Benzyl alcohol (BA) effectively lowers blood pressure and improves vascular and kidney function in a mouse model of hypertension. This study highlights BA as a potential therapeutic agent for managing pediatric hypertension and its associated complications.

Area of Science:

  • Metabolomics
  • Cardiovascular Research
  • Pediatric Nephrology

Background:

  • Pediatric hypertension is complex, with metabolic factors contributing to its development.
  • Metabolomics analysis identified Benzyl alcohol (BA) as a potential therapeutic target.

Purpose of the Study:

  • To investigate the therapeutic effects of Benzyl alcohol (BA) on Angiotensin II (Ang II)-induced vascular and renal injury in mice.
  • To evaluate BA's impact on blood pressure, vascular remodeling, and kidney function.

Main Methods:

  • Established a vascular remodeling model in mice using Angiotensin II (Ang II) infusion.
  • Utilized bioinformatics for metabolite identification.
  • Assessed blood pressure, vascular structure (HE, Masson staining), and kidney pathology (HE).
  • Measured serum markers of kidney function (urea nitrogen, creatinine, cystatin C).

Main Results:

  • Benzyl alcohol (BA) significantly reduced systolic (11.58%) and diastolic (14.62%) blood pressure.
  • BA treatment restored impaired vasodilation reactivity.
  • BA attenuated Ang II-induced vascular thickening, collagen deposition, and renal structural damage.
  • BA reversed elevated serum urea nitrogen, creatinine, and cystatin C levels.

Conclusions:

  • Benzyl alcohol (BA) demonstrates significant potential in ameliorating Angiotensin II (Ang II)-induced hypertension.
  • BA improves vasodilatory response, reduces vascular remodeling, and protects against renal injury.
  • BA represents a promising therapeutic candidate for pediatric hypertension management.
Abstract

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
445
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
394
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
544
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
273
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
386